

W Marston Linehan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1429121/w-marston-linehan-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

313
papers

32,095
citations

89
h-index

175
g-index

332
ext. papers

36,773
ext. citations

7.7
avg, IF

6.79
L-index

#	Paper	IF	Citations
313	Seventh BHD international symposium: recent scientific and clinical advancement.. <i>Oncotarget</i> , 2022 , 13, 173-181	3.3	1
312	MPA software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays.. <i>Cell Reports Methods</i> , 2022 , 2, 100136		0
311	Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers.. <i>IScience</i> , 2022 , 104463	6.1	
310	A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells. <i>Cancers</i> , 2022 , 14, 2643	6.6	0
309	Atherosclerotic Plaque Burden on Abdominal CT: Automated Assessment With Deep Learning on Noncontrast and Contrast-enhanced Scans. <i>Academic Radiology</i> , 2021 , 28, 1491-1499	4.3	9
308	Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. <i>Abdominal Radiology</i> , 2021 , 46, 3301-3308	3	1
307	Comprehensive characterization of Alu-mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families. <i>Human Mutation</i> , 2021 , 42, 520-529	4.7	1
306	Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2021 , 60, 434-446	5	1
305	Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. <i>European Urology Oncology</i> , 2021 ,	6.7	9
304	Therapeutic inhibition of HIF-2 α reverses polycythemia and pulmonary hypertension in murine models of human diseases. <i>Blood</i> , 2021 , 137, 2509-2519	2.2	6
303	Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets. <i>Science</i> , 2021 , 373, 236-241	33.3	26
302	A deep-learning based artificial intelligence (AI) approach for differentiation of clear cell renal cell carcinoma from oncocytoma on multi-phasic MRI. <i>Clinical Imaging</i> , 2021 , 77, 291-298	2.7	4
301	Macronodular adrenal hyperplasia masquerading as an upper pole renal mass. <i>Urology Case Reports</i> , 2021 , 37, 101603	0.5	
300	Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma. <i>Urology</i> , 2021 , 149, 89-97	1.6	10
299	Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 134.e1-134.e8	2.8	2
298	MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2021 , 12, 5375-5384	4.5	1
297	Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. <i>Blood</i> , 2021 , 137, 126-137	2.2	14

296	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021 , 12, 808	17.4	26
295	Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management. <i>Genes</i> , 2021 , 12,	4.2	3
294	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. <i>Cancer</i> , 2021 , 127, 3957-3966	6.4	1
293	X-Capsular Incision for Tumor Enucleation (X-CITE)-Technique: A Method to Maximize Renal Parenchymal Preservation for Completely Endophytic Renal Tumors. <i>Urology</i> , 2021 , 154, 315-319	1.6	0
292	The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. <i>Nature Structural and Molecular Biology</i> , 2021 , 28, 662-670	17.6	4
291	Reoperative Partial Nephrectomy-Does Previous Surgical Footprint Impact Outcomes?. <i>Journal of Urology</i> , 2021 , 206, 539-547	2.5	0
290	Intravitreal treatment of severe ocular von Hippel-Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial. <i>Clinical and Experimental Ophthalmology</i> , 2021 , 49, 1048-1059	2.4	1
289	Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer. <i>Science Signaling</i> , 2021 , 14,	8.8	21
288	Tobacco smoking induces metabolic reprogramming of renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	5
287	Blood and lymphatic systems are segregated by the FLCN tumor suppressor. <i>Nature Communications</i> , 2020 , 11, 6314	17.4	5
286	Salvage robotic transmesenteric off-clamp partial nephrectomy after multiple prior open kidney surgeries. <i>Urology Case Reports</i> , 2020 , 30, 101135	0.5	
285	Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. <i>Clinical Imaging</i> , 2020 , 68, 14-19	2.7	4
284	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1146-1153	2.2	21
283	Long-term Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma. <i>Urology</i> , 2020 , 140, 85-90	1.6	7
282	An Oncometabolite Isomer Rapidly Induces a Pathophysiological Protein Modification. <i>ACS Chemical Biology</i> , 2020 , 15, 856-861	4.9	0
281	Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2020 , 11, 3596-3603	4.5	5
280	Phase II study of the oral HIF-2 α inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5003-5003	2.2	25
279	Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5004-5004	2.2	25

278	Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy. <i>Cell Reports</i> , 2020 , 30, 1798-1810.e4	10.6	32
277	A FLCN-TFE3 Feedback Loop Prevents Excessive Glycogenesis and Phagocyte Activation by Regulating Lysosome Activity. <i>Cell Reports</i> , 2020 , 30, 1823-1834.e5	10.6	11
276	FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland. <i>Biochemical and Biophysical Research Communications</i> , 2020 , 522, 931-938	3.4	2
275	Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite. <i>Journal of Biological Chemistry</i> , 2020 , 295, 13410-13418	5.4	1
274	A germline 1;3 translocation disrupting the gene: a novel genetic cause for von Hippel-Lindau. <i>Journal of Medical Genetics</i> , 2020 ,	5.8	2
273	Fumarate hydratase-deficient renal cell carcinoma cells respond to asparagine by activation of the unfolded protein response and stimulation of the hexosamine biosynthetic pathway. <i>Cancer & Metabolism</i> , 2020 , 8, 7	5.4	1
272	Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments. <i>Genes Chromosomes and Cancer</i> , 2020 , 59, 472-483	5	2
271	Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel-Lindau Disease. <i>Radiology</i> , 2020 , 295, 583-590	20.5	2
270	Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90. <i>Cell Reports</i> , 2019 , 26, 1344-1356.e5	10.6	23
269	MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. <i>Cancer Science</i> , 2019 , 110, 1897-1908	6.9	30
268	TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease. <i>Molecular Cancer Research</i> , 2019 , 17, 1613-1626	6.6	12
267	The Metabolic Basis of Kidney Cancer. <i>Cancer Discovery</i> , 2019 , 9, 1006-1021	24.4	68
266	Birt-Hogg-Dubé Syndrome initially diagnosed as tuberous sclerosis complex. <i>JAAD Case Reports</i> , 2019 , 5, 368-371	1.4	5
265	Salvage Surgery After Percutaneous Ablation of Renal Mass in Solitary Kidney in a Patient With Von Hippel-Lindau. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e482-e484	3.3	
264	Metabolic Labeling of Cultured Mammalian Cells for Stable Isotope-Resolved Metabolomics: Practical Aspects of Tissue Culture and Sample Extraction. <i>Methods in Molecular Biology</i> , 2019 , 1928, 1-27	1.4	8
263	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. <i>European Urology</i> , 2019 , 76, 754-764	10.2	42
262	The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. <i>Nature Reviews Urology</i> , 2019 , 16, 539-552	5.5	160
261	Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau. <i>Urology Case Reports</i> , 2019 , 27, 100922	0.5	1

260	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2019 , 179, 964-983.e31	17.1	173
259	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019 , 25, 6302-6308	12.9	6
258	Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice. <i>ELife</i> , 2019 , 8,	8.9	12
257	A chemoproteomic portrait of the oncometabolite fumarate. <i>Nature Chemical Biology</i> , 2019 , 15, 391-400	11.7	37
256	Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc. <i>Scientific Reports</i> , 2019 , 9, 18409	4.9	5
255	Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity. <i>Genes and Development</i> , 2019 , 33, 1641-1656	12.6	3
254	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 1-6	3.3	28
253	Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2 α Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2019 , 75, 882-884	10.2	1
252	Photoinducible Oncometabolite Detection. <i>ChemBioChem</i> , 2019 , 20, 360-365	3.8	11
251	Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease. <i>Cancer</i> , 2019 , 125, 1060-1069	6.4	14
250	CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors. <i>Urology</i> , 2019 , 124, 91-97	1.6	9
249	Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors. <i>Radiology</i> , 2019 , 290, 116-124	20.5	3
248	Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2018 , 173, 540-542	56.2	23
247	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018 , 23, 313-326.e5	10.6	295
246	In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1631-1638	5.6	9
245	Acute loss of iron-sulfur clusters results in metabolic reprogramming and generation of lipid droplets in mammalian cells. <i>Journal of Biological Chemistry</i> , 2018 , 293, 8297-8311	5.4	43
244	Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 344-352	4	4
243	Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease. <i>JAMA Oncology</i> , 2018 , 4, 124-126	13.4	30

242	FLCN: The causative gene for Birt-Hogg-Dubé syndrome. <i>Gene</i> , 2018 , 640, 28-42	3.8	66
241	Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5977-5989	12.9	44
240	Evaluation of Recipients of Positive and Negative Secondary Findings Evaluations in a Hybrid CLIA-Research Sequencing Pilot. <i>American Journal of Human Genetics</i> , 2018 , 103, 358-366	11	24
239	The origin, evolution and route to metastasis of clear cell RCC. <i>Nature Reviews Nephrology</i> , 2018 , 14, 538-540	14.9	5
238	Superiority of Ga-DOTATATE over F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 787-797	8.8	38
237	Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. <i>Journal of Clinical Oncology</i> , 2018 , JCO2018792309	2.2	20
236	ONC201 kills breast cancer cells by targeting mitochondria. <i>Oncotarget</i> , 2018 , 9, 18454-18479	3.3	45
235	Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. <i>Cancer Research</i> , 2018 , 78, 6539-6548	10.1	9
234	The Warburg effect in hominis: isotope-resolved metabolism in ccRCC. <i>Nature Reviews Urology</i> , 2018 , 15, 731-732	5.5	2
233	Targeting loss of the Hippo signaling pathway in -deficient papillary kidney cancers. <i>Oncotarget</i> , 2018 , 9, 10723-10733	3.3	18
232	BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. <i>Human Molecular Genetics</i> , 2018 , 27, 2712-2724	5.6	6
231	Discovering Targets of Non-enzymatic Acylation by Thioester Reactivity Profiling. <i>Cell Chemical Biology</i> , 2017 , 24, 231-242	8.2	50
230	Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma. <i>Genes Chromosomes and Cancer</i> , 2017 , 56, 484-492	5	17
229	Managing Renal Cell Carcinoma Associated Paraneoplastic Syndrome with Nephron-sparing Surgery in a Patient with von Hippel-Lindau. <i>Urology Case Reports</i> , 2017 , 13, 101-103	0.5	
228	Kidney cancer in 2016: RCC - advances in targeted therapeutics and genomics. <i>Nature Reviews Urology</i> , 2017 , 14, 76-78	5.5	10
227	Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2017 , 7, 1221-1223	24.4	7
226	Recommendations for the Management of Rare Kidney Cancers. <i>European Urology</i> , 2017 , 72, 974-983	10.2	27
225	Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). <i>Genes Chromosomes and Cancer</i> , 2017 , 56, 719-729	5	8

224	Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline Mutation. <i>Urology Case Reports</i> , 2017 , 13, 107-109	0.5	1
223	A mouse model of renal cell carcinoma. <i>Nature Medicine</i> , 2017 , 23, 802-803	50.5	1
222	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal -Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-14	3.6	4
221	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. <i>Oncotarget</i> , 2017 , 8, 17628-17642	3.3	10
220	Hereditary Renal Cell Carcinoma 2017 , 19-82		1
219	H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation. <i>Human Molecular Genetics</i> , 2017 , 26, 354-366	5.6	15
218	SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	73
217	Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney. <i>International Urology and Nephrology</i> , 2016 , 48, 1817-1821	2.3	13
216	Co-opting a Bioorthogonal Reaction for Oncometabolite Detection. <i>Journal of the American Chemical Society</i> , 2016 , 138, 15813-15816	16.4	17
215	The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. <i>Nature Communications</i> , 2016 , 7, 12037	17.4	37
214	Postoperative elevation in creatine kinase and its impact on renal function in patients undergoing complex partial nephrectomy. <i>International Urology and Nephrology</i> , 2016 , 48, 1047-1053	2.3	6
213	Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer. <i>Pharmaceutical Research</i> , 2016 , 33, 2459-69	4.5	6
212	Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, e76-9	2.2	3
211	Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer. <i>Cancer Research</i> , 2016 , 76, 2177-85	10.1	56
210	PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study. <i>Abdominal Radiology</i> , 2016 , 41, 109-18	3	29
209	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016 , 374, 135-45	59.2	753
208	Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease. <i>Journal of Neurosurgery</i> , 2016 , 124, 971-6	3.2	23
207	Loss of Folliculin Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure. <i>Stem Cells</i> , 2016 , 34, 1068-82	5.8	21

206	Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumours. <i>Nature Communications</i> , 2016 , 7, 11588	17.4	19
205	SnapShot: Renal Cell Carcinoma. <i>Cancer Cell</i> , 2016 , 29, 610-610.e1	24.3	26
204	Hypoxia-Inducible Factor 2 α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. <i>Neoplasia</i> , 2016 , 18, 567-76	6.4	13
203	Genetic predisposition to kidney cancer. <i>Seminars in Oncology</i> , 2016 , 43, 566-574	5.5	77
202	Targeting HIF2 α in Clear-Cell Renal Cell Carcinoma. <i>Cancer Cell</i> , 2016 , 30, 515-517	24.3	21
201	Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes. <i>Journal of Endourology</i> , 2016 , 30, 1219-1226	2.7	10
200	The Metabolic Basis of Kidney Cancer 2015 , 89-102		1
199	Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 390-7	27.4	999
198	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 167.e13-20	2.8	18
197	Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E1624-31	11.5	59
196	Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birt-Hogg-Dubé tumors. <i>Modern Pathology</i> , 2015 , 28, 1458-69	9.8	19
195	Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2015 , 151, 1096-102	5.1	13
194	Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome. <i>Nature Reviews Urology</i> , 2015 , 12, 558-69	5.5	116
193	Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma. <i>Hepatology</i> , 2015 , 62, 1122-31	11.2	53
192	Metabolism and oxidative stress response pathways in kidney cancer: a tale of chance and necessity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 220-5	7.1	3
191	Comedonal and Cystic Fibrofolliculomas in Birt-Hogg-Dubé Syndrome. <i>JAMA Dermatology</i> , 2015 , 151, 770-4	5.1	19
190	Clinical Features, Genetics and Potential Therapeutic Approaches for Birt-Hogg-Dubé Syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 15-29	1.1	35
189	New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease. <i>Clinical Cancer Research</i> , 2015 , 21, 10-7	12.9	75

188	Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC). <i>PLoS ONE</i> , 2015 , 10, e0140257	3.7	42
187	Tonantzitlolone cytotoxicity toward renal cancer cells is PKC β and HSF1-dependent. <i>Oncotarget</i> , 2015 , 6, 29963-74	3.3	12
186	The genetic basis of pheochromocytoma and paraganglioma: implications for management. <i>Urology</i> , 2014 , 83, 1225-32	1.6	33
185	Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. <i>Human Molecular Genetics</i> , 2014 , 23, 5706-19	5.6	44
184	The somatic genomic landscape of chromophobe renal cell carcinoma. <i>Cancer Cell</i> , 2014 , 26, 319-330	24.3	521
183	Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions. <i>Journal of the American College of Surgeons</i> , 2014 , 218, 997-1003	4.4	13
182	Decade in review-kidney cancer: discoveries, therapies and opportunities. <i>Nature Reviews Urology</i> , 2014 , 11, 614-6	5.5	19
181	Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. <i>Nature Reviews Urology</i> , 2014 , 11, 465-75	5.5	169
180	Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. <i>Journal of Clinical Oncology</i> , 2014 , 32, 431-7	2.2	95
179	Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 27.e15-21	2.8	7
178	Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. <i>Cell Reports</i> , 2014 , 7, 1679-1690	10.6	216
177	Hereditary leiomyomatosis and renal cell carcinoma. <i>International Journal of Nephrology and Renovascular Disease</i> , 2014 , 7, 253-60	2.5	86
176	Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. <i>Familial Cancer</i> , 2014 , 13, 637-44	3	170
175	Looking forward, looking back-10 years in urology. <i>Nature Reviews Urology</i> , 2014 , 11, 649-55	5.5	4
174	Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer. <i>Cancer Cell</i> , 2014 , 26, 840-850	24.3	67
173	Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 23.e9-13	2.8	20
172	Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK. <i>Cell Reports</i> , 2014 , 7, 412-423	10.6	70
171	Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. <i>PLoS ONE</i> , 2014 , 9, e85621	3.7	43

170	Englerin A stimulates PKC α to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. <i>Cancer Cell</i> , 2013 , 23, 228-37	24.3	61
169	A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. <i>Molecular Cancer Research</i> , 2013 , 11, 1061-1071	6.6	111
168	Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. <i>Seminars in Oncology</i> , 2013 , 40, 511-20	5.5	31
167	Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 181-6	2.2	336
166	Metabolism of kidney cancer: from the lab to clinical practice. <i>European Urology</i> , 2013 , 63, 244-51	10.2	54
165	Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. <i>Journal of Urology</i> , 2013 , 190, 1990-8	2.5	66
164	The metabolic basis of kidney cancer. <i>Seminars in Cancer Biology</i> , 2013 , 23, 46-55	12.7	100
163	Diagnosis and management of BHD-associated kidney cancer. <i>Familial Cancer</i> , 2013 , 12, 397-402	3	65
162	Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma. <i>Clinical Cancer Research</i> , 2013 , 19, 42-9	12.9	31
161	Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 3345-52	12.9	139
160	Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4584-4584	2.2	3
159	Defining early-onset kidney cancer: Implications for genetic counseling.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 342-342	2.2	1
158	Clinical evaluation of 2-(18F) fluoro-2 deoxy-D-glucose PET/ CT in hereditary leiomyomatosis and renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 383-383	2.2	2
157	Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. <i>PLoS ONE</i> , 2013 , 8, e72179	3.7	71
156	Paragangliomas of the urinary bladder: Experience at the National Cancer Institute.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 307-307	2.2	
155	The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dub δ syndrome is required for murine B-cell development. <i>Blood</i> , 2012 , 120, 1254-61	2.2	52
154	Kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 948-51	2.8	28
153	Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. <i>Journal of Urology</i> , 2012 , 188, 2063-71	2.5	175

152	A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. <i>Cancer Genetics</i> , 2012 , 205, 377-90	2.3	47
151	Correlation of magnetic resonance imaging tumor volume with histopathology. <i>Journal of Urology</i> , 2012 , 188, 1157-1163	2.5	152
150	Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. <i>Journal of Urology</i> , 2012 , 188, 2152-2157	2.5	199
149	Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges. <i>Journal of Natural Products</i> , 2012 , 75, 1632-6	4.9	12
148	Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1750-64	9.7	70
147	Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. <i>Genome Research</i> , 2012 , 22, 2089-100	9.7	162
146	Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. <i>Oncologist</i> , 2012 , 17, 46-54	5.7	139
145	Translocation renal cell carcinomas in adults: a single-institution experience. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 654-62	6.7	79
144	Targeting HIF2 α translation with Tempol in VHL-deficient clear cell renal cell carcinoma. <i>Oncotarget</i> , 2012 , 3, 1472-82	3.3	19
143	Treatment of Advanced Renal Cell Carcinoma 2012 , 1475-1491.e5		2
142	Reductive carboxylation supports growth in tumour cells with defective mitochondria. <i>Nature</i> , 2011 , 481, 385-8	50.4	853
141	Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. <i>PLoS Genetics</i> , 2011 , 7, e1002312	6	140
140	Robot-assisted laparoscopic partial adrenalectomy: initial experience. <i>Urology</i> , 2011 , 77, 775-80	1.6	41
139	Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2011 , 2, 515-26	4.5	64
138	Differential genetic expression in large versus small clear cell renal cell carcinoma: results from microarray analysis. <i>Journal of Cancer</i> , 2011 , 2, 271-9	4.5	4
137	Familial renal cancer: molecular genetics and surgical management. <i>International Journal of Surgical Oncology</i> , 2011 , 2011, 658767	0.9	18
136	Robot-assisted laparoscopic partial adrenalectomy for pheochromocytoma: the National Cancer Institute technique. <i>European Urology</i> , 2011 , 60, 118-24	10.2	49
135	The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. <i>Cancer Cell</i> , 2011 , 20, 315-27	24.3	152

134	Impact of genetics on the diagnosis and treatment of renal cancer. <i>Current Urology Reports</i> , 2011 , 12, 47-55	2.9	17
133	Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubouché syndrome. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 466-77	5	44
132	Catecholamine metabolomic and secretory phenotypes in pheochromocytoma. <i>Endocrine-Related Cancer</i> , 2011 , 18, 97-111	5.7	127
131	Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. <i>Clinical Chemistry</i> , 2011 , 57, 411-20	5.5	225
130	Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2 α -induced gene expression. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 2113-5	2.9	16
129	Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. <i>Cell Cycle</i> , 2010 , 9, 4183-9	4.7	25
128	Molecular diagnosis and therapy of kidney cancer. <i>Annual Review of Medicine</i> , 2010 , 61, 329-43	17.4	135
127	Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF- β signaling. <i>Molecular Cancer</i> , 2010 , 9, 160	42.1	71
126	A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. <i>Journal of Translational Medicine</i> , 2010 , 8, 8	8.5	25
125	Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. <i>Journal of Urology</i> , 2010 , 184, 1855-9	3.5	58
124	The genetic basis of kidney cancer: a metabolic disease. <i>Nature Reviews Urology</i> , 2010 , 7, 277-85	5.5	516
123	Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 757-66	6.7	96
122	Targeted therapies for non-clear renal cell carcinoma. <i>Targeted Oncology</i> , 2010 , 5, 119-29	5	27
121	UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. <i>Cancer Genetics and Cytogenetics</i> , 2010 , 196, 45-55		112
120	Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. <i>PLoS ONE</i> , 2010 , 5, e15793	3.7	103
119	Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1 α stabilization by glucose-dependent generation of reactive oxygen species. <i>Molecular and Cellular Biology</i> , 2009 , 29, 4080-90	4.8	181
118	Genetic basis of bilateral renal cancer: implications for evaluation and management. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3731-3	2.2	15
117	Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 18722-7	11.5	184

116	Targeting the Met signaling pathway in renal cancer. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 785-93	3.5	60
115	Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. <i>Cancer</i> , 2009 , 115, 2247-51	6.4	21
114	Hereditary kidney cancer: unique opportunity for disease-based therapy. <i>Cancer</i> , 2009 , 115, 2252-61	6.4	89
113	VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2009 , 41, 753-6	5.6	43
112	Initial experience with robot assisted partial nephrectomy for multiple renal masses. <i>Journal of Urology</i> , 2009 , 182, 1280-6	2.5	52
111	The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dubé gene pathway. <i>Cancer Genetics and Cytogenetics</i> , 2008 , 180, 100-9		43
110	Robotic partial nephrectomy for complex renal tumors: surgical technique. <i>European Urology</i> , 2008 , 53, 514-21	10.2	187
109	Kidney cancer: opportunity for disease specific targeted therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 542	2.8	4
108	Identification and characterization of a novel folliculin-interacting protein FNIP2. <i>Gene</i> , 2008 , 415, 60-7	3.8	143
107	Robotic partial nephrectomy for renal hilar tumors: a multi-institutional analysis. <i>Journal of Urology</i> , 2008 , 180, 2353-6; discussion 2356	2.5	131
106	Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. <i>Journal of Urology</i> , 2008 , 179, 67-70	2.5	59
105	Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. <i>Clinical Cancer Research</i> , 2008 , 14, 4726-34	12.9	422
104	Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. <i>Archives of Dermatology</i> , 2008 , 144, 1584-92		65
103	Kidney-targeted Birt-Hogg-Dubé gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 140-54	9.7	194
102	Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 779-90	5.4	41
101	Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. <i>Journal of Urology</i> , 2007 , 177, 2074-9; discussion 2079-80	2.5	191
100	Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). <i>Surgery</i> , 2007 , 142, 814-8; discussion 818-21	3.6	196
99	Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. <i>Clinical Cancer Research</i> , 2007 , 13, 671s-679s	12.9	113

98	Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 175, 1044-53	10.2	256
97	Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomas. <i>JAMA Ophthalmology</i> , 2007 , 125, 239-45		58
96	Targeting VEGF receptors in kidney cancer. <i>Lancet Oncology</i> , 2007 , 8, 956-7	21.7	14
95	Protein expression profiling in the spectrum of renal tumors. <i>FASEB Journal</i> , 2007 , 21, A181	0.9	
94	Identification of the genes for kidney cancer. <i>Cancer Biology and Therapy</i> , 2006 , 5, 696-9	4.6	
93	High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4505-9	5.6	255
92	Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression. <i>Journal of Biomolecular Screening</i> , 2006 , 11, 678-87		22
91	Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 15552-7	11.5	367
90	Multiple painful cutaneous nodules and renal mass. <i>Journal of the American Academy of Dermatology</i> , 2006 , 55, 683-6	4.5	14
89	Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. <i>American Journal of Human Genetics</i> , 2005 , 76, 1023-33	11	304
88	Partial adrenalectomy: the National Cancer Institute experience. <i>Urology</i> , 2005 , 66, 19-23	1.6	71
87	Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. <i>Journal of Urology</i> , 2005 , 173, 1482-6	2.5	221
86	The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. <i>BJU International</i> , 2005 , 95 Suppl 2, 2-7	5.6	39
85	HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. <i>Cancer Cell</i> , 2005 , 8, 143-53	24.3	740
84	High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 931-5	9.7	184
83	Management of von Hippel-Lindau-associated kidney cancer. <i>Nature Reviews Urology</i> , 2005 , 2, 248-55		34
82	Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. <i>Modern Pathology</i> , 2004 , 17, 998-1011	9.8	106
81	Focus on kidney cancer. <i>Cancer Cell</i> , 2004 , 6, 223-8	24.3	105

80	Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. <i>Human Mutation</i> , 2004 , 23, 40-6	4.7	78
79	The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. <i>Journal of Urology</i> , 2004 , 172, 63-5	2.5	156
78	Parenchymal sparing surgery for central renal tumors in patients with hereditary renal cancers. <i>Journal of Urology</i> , 2004 , 172, 49-53	2.5	14
77	Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. <i>Journal of Urology</i> , 2004 , 172, 1256-61	2.5	88
76	Endolymphatic sac tumors in von Hippel-Lindau disease. <i>Journal of Neurosurgery</i> , 2004 , 100, 480-7	3.2	64
75	Genetic basis of cancer of the kidney: disease-specific approaches to therapy. <i>Clinical Cancer Research</i> , 2004 , 10, 6282S-9S	12.9	159
74	Studying cancer families to identify kidney cancer genes. <i>Annual Review of Medicine</i> , 2003 , 54, 217-33	17.4	54
73	Hereditary renal cancers. <i>Radiology</i> , 2003 , 226, 33-46	20.5	164
72	Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[¹⁸ F]Fluorodopamine Positron Emission Tomography. <i>Journal of Urology</i> , 2003 , 169, 274-275	2.5	19
71	A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2003 , 169, 357-360	2.5	16
70	The genetic basis of cancer of the kidney. <i>Journal of Urology</i> , 2003 , 170, 2163-72	2.5	388
69	von Hippel-Lindau disease. <i>Lancet, The</i> , 2003 , 361, 2059-67	40	1083
68	Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. <i>American Journal of Human Genetics</i> , 2003 , 73, 95-106	11	479
67	The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. <i>Cancer Cell</i> , 2002 , 1, 247-55	24.3	388
66	Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. <i>Cancer Cell</i> , 2002 , 2, 157-64	24.3	705
65	Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. <i>Cancer</i> , 2002 , 94, 690-9	6.4	47
64	Biochemical diagnosis of pheochromocytoma: which test is best?. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 1427-34	27.4	792
63	Renal tumors in the Birt-Hogg-Dubé syndrome. <i>American Journal of Surgical Pathology</i> , 2002 , 26, 1542-52	6.7	449

62	Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dub \square syndrome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002 , 11, 393-400	4	162
61	Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. <i>Annals of Internal Medicine</i> , 2001 , 134, 315-29	8	402
60	Partial adrenalectomy in patients with multiple adrenal tumors. <i>Current Urology Reports</i> , 2001 , 2, 19-23	2.9	11
59	Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: utilization of microdissection and polymerase chain reaction in archival tissues. <i>Diagnostic Cytopathology</i> , 2001 , 24, 328-32	1.4	18
58	Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 1999-2008	5.6	224
57	PARENCHYMAL SPARING SURGERY IN A PATIENT WITH MULTIPLE BILATERAL PAPILLARY RENAL CANCER. <i>Journal of Urology</i> , 2001 , 165, 1623-1624	2.5	7
56	Birt-Hogg-Dub \square syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. <i>American Journal of Human Genetics</i> , 2001 , 69, 876-82	11	285
55	PARENCHYMAL SPARING SURGERY IN PATIENTS WITH HEREDITARY RENAL CELL CARCINOMA: 10-YEAR EXPERIENCE. <i>Journal of Urology</i> , 2001 , 165, 777-781	2.5	159
54	LACK OF RETROPERITONEAL LYMPHADENOPATHY PREDICTS SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2001 , 166, 68-72	2.5	141
53	EXPRESSION STUDIES AND MUTATIONAL ANALYSIS OF THE ANDROGEN REGULATED HOMEBOX GENE NKX3.1 IN BENIGN AND MALIGNANT PROSTATE EPITHELIUM. <i>Journal of Urology</i> , 2001 , 165, 1329-1334	2.5	70
52	Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. <i>Drug Development Research</i> , 2000 , 49, 34-42	5.1	120
51	Development of a prostate cDNA microarray and statistical gene expression analysis package 2000 , 28, 12-22		54
50	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. <i>Electrophoresis</i> , 2000 , 21, 2235-42	3.6	232
49	PREVALENCE OF MICROSCOPIC TUMORS IN NORMAL APPEARING RENAL PARENCHYMA OF PATIENTS WITH HEREDITARY PAPILLARY RENAL CANCER. <i>Journal of Urology</i> , 2000 , 163, 431-433	2.5	76
48	Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip 2000 , 49, 34		2
47	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines 2000 , 21, 2235		2
46	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines 2000 , 21, 2235		6
45	Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. <i>Oncogene</i> , 1999 , 18, 1205-8	9.2	101

44	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. <i>Oncogene</i> , 1999 , 18, 2343-50	9.2	438
43	Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology 1999 , 87, 231-237		10
42	Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. <i>Journal of Urology</i> , 1999 , 162, 43-5	2.5	92
41	Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. <i>Journal of Urology</i> , 1999 , 162, 659-64	2.5	207
40	Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. <i>Journal of Urology</i> , 1999 , 161, 1475-9	2.5	189
39	MANAGEMENT OF HEREDITARY PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU KINDREDS WITH PARTIAL ADRENALECTOMY. <i>Journal of Urology</i> , 1999 , 161, 395-398	2.5	79
38	Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. <i>American Journal of Pathology</i> , 1999 , 155, 517-26	5.8	199
37	Trisomy 7-harboring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. <i>Nature Genetics</i> , 1998 , 20, 66-9	36.3	253
36	Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. <i>Human Mutation</i> , 1998 , 12, 417-23	4.7	406
35	Allelic Loss on Chromosome 8p in BRCA-1 Mutation Positive Breast/Ovarian Cancers. <i>Breast Journal</i> , 1998 , 4, 9-12	1.2	4
34	PSEUDOTUMORS AFTER RENAL PARENCHYMAL SPARING SURGERY. <i>Journal of Urology</i> , 1998 , 159, 1148-1151	2.5	9
33	Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. <i>American Journal of Pathology</i> , 1998 , 153, 223-31	5.8	199
32	Familial renal oncocytoma: clinicopathological study of 5 families. <i>Journal of Urology</i> , 1998 , 160, 335-40	2.5	108
31	Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene 1998 , 12, 417		12
30	Pulmonary infarcts can mimic pulmonary metastases from renal cancer. <i>Journal of Urology</i> , 1997 , 158, 1688-90	2.5	7
29	Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. <i>Journal of Urology</i> , 1997 , 158, 1675-8	2.5	105
28	Epididymal cystadenomas in von Hippel-Lindau disease. <i>Urology</i> , 1997 , 49, 926-31	1.6	78
27	Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. <i>Urology</i> , 1997 , 50, 295-301	1.6	22

26	Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. <i>Oncogene</i> , 1997 , 15, 2233-9	9.2	254
25	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. <i>Nature Genetics</i> , 1997 , 16, 68-73	36.3	1289
24	Fine-needle aspiration of metastatic clear cell carcinoma of the kidney. <i>Cancer</i> , 1997 , 81, 180-186	6.4	21
23	Imaging features of hereditary papillary renal cancers. <i>Journal of Computer Assisted Tomography</i> , 1997 , 21, 737-41	2.2	55
22	Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. <i>Human Mutation</i> , 1996 , 8, 348-57	4.7	358
21	Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. <i>World Journal of Urology</i> , 1996 , 14 Suppl 1, S2-7	4	7
20	Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan 1996 , 8, 348		17
19	Original Articles: Kidney Cancer: Parenchymal Sparing Surgery in Patients With Hereditary Renal Cell Carcinoma. <i>Journal of Urology</i> , 1995 , 153, 913-916	2.5	80
18	Original Articles: Kidney Cancer: Hereditary Papillary Renal Cell Carcinoma: Clinical Studies in 10 Families. <i>Journal of Urology</i> , 1995 , 153, 907-912	2.5	154
17	Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. <i>Journal of Urology</i> , 1995 , 153, 22-6	2.5	122
16	Prevalence of Microscopic lesions in Grossly Normal Renal Parenchyma from Patients with von Hippel-Lindau Disease, Sporadic Renal Cell Carcinoma and No Renal Disease: Clinical Implications. <i>Journal of Urology</i> , 1995 , 154, 2010-2015	2.5	142
15	Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. <i>Human Mutation</i> , 1995 , 5, 66-75	4.7	475
14	Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma. <i>Genes Chromosomes and Cancer</i> , 1995 , 13, 151-6	5	41
13	Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. <i>Genes Chromosomes and Cancer</i> , 1994 , 11, 15-20	5	31
12	Hereditary papillary renal cell carcinoma. <i>Journal of Urology</i> , 1994 , 151, 561-6	2.5	235
11	Evaluation of color Doppler intraoperative ultrasound in parenchymal sparing renal surgery. <i>Journal of Urology</i> , 1994 , 152, 1984-7	2.5	35
10	Identification of the von Hippel-Lindau disease tumor suppressor gene. <i>Science</i> , 1993 , 260, 1317-20	33.3	2363
9	Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. <i>Journal of Urology</i> , 1993 , 150, 463-6	2.5	104

8	Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. <i>Journal of Surgical Oncology</i> , 1993 , 53, 252-5	2.8	3
7	A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. <i>Cancer</i> , 1992 , 69, 213-8	6.4	17
6	A report of familial carotid body tumors and multiple extra-adrenal pheochromocytomas. <i>Journal of Urology</i> , 1991 , 145, 1040-2	2.5	28
5	Surgical management of pheochromocytoma with the use of metyrosine. <i>Annals of Surgery</i> , 1990 , 212, 621-8	7.8	79
4	Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. <i>Journal of Urology</i> , 1990 , 144, 614-7; discussion 617-8	2.5	80
3	The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice. <i>Prostate</i> , 1987 , 10, 189-97	4.2	18
2	Aids Case for Diagnosis, 1986 Military Medicine. <i>Military Medicine</i> , 1986 , 151, M49-M56	1.3	
1	Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNF α cytotoxicity		1